Rishabh Jain: Can Immunotherapy Before Surgery Change the Future of Resectable HCC?
Rishabh Jain/X

Rishabh Jain: Can Immunotherapy Before Surgery Change the Future of Resectable HCC?

Rishabh Jain, Medical Consultant at Renova Hospital (RHL), shared a post on X:

“Can immunotherapy before surgery change the future of resectable HCC?

PRIME-HCC | Phase Ib | Lancet Oncology 2026

33 patients received neoadjuvant nivolumab + ipilimumab.

 Key results:

  • 22% complete pathological response (6/27)
  • 33% major pathological response (≥70%)
  • 91% underwent surgery • 9% grade 3 treatment-related AEs

The ctDNA signal is particularly interesting!

2-year recurrence-free survival:

  •  ctDNA undetectable: 82%
  •  ctDNA detectable: 29% (p=0.049)

Verdict: Neoadjuvant dual checkpoint blockade appears feasible in selected resectable HCC. ctDNA may help identify recurrence risk, but these exploratory findings need validation.

Small, single-arm study. Not practice-changing yet.”

Title: Neoadjuvant nivolumab plus ipilimumab in surgically resectable hepatocellular carcinoma (PRIME-HCC): a prospective, phase 1b, single-arm trial and translational analyses

Authors: Antonio D’Alessio, Claudia Angela Maria Fulgenzi, Madhava Pai, Alexandra Emilia Schlaak, Duncan Spalding, Ira Godbole, Robert D Goldin, Nicole Acuti, Caroline Ward, Georgios Nteliopoulos, Vincent Yip, Sarah Slater, Poyyamozhi Rajagopal, Mikael Sodergren, Paul Tait, Nagy Habib, Robert Thomas, Eslam Maher, Francesco A Mauri, Alessio Cortellini, Julian R Marchesi, Bertram Bengsch, Rohini Sharma, David James Pinato

Read the Full Article on The Lancet Oncology

Rishabh Jain: Can Immunotherapy Before Surgery Change the Future of Resectable HCC?

You can also read: Nivolumab With deb-TACE in Liver-Limited Hepatocellular Carcinoma

Rishabh Jain: Can Immunotherapy Before Surgery Change the Future of Resectable HCC?